Plasma EBV DNA Monitoring in Post-treatment NPC Patients

Taichung Veterans General Hospital

Status: Completed

Conditions: EBV; Nasopharyngeal Carcinoma; Radiotherapy; NPC

Study type: Observational

Funder types: Other

Identifiers

NCT03973723

CG11133

Details and patient eligibility

About

Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.

Full description

The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy with/without chemotherapy and no recurrence/metastasis before entry this study from five hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do risk grouping for survival analyses according to the blood test results.

Enrollment: 441 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• histologically-proven nasopharyngeal carcinoma without distant metastasis (M0) at initial presentation
• finished curative radiotherapy (with/without chemotherapy) within 3 years

Exclusion criteria

• no occurrence of documented recurrence/metastasis before entry

Trial design

441 participants in 1 patient group

Patients with NPC after treatment

Description:

All patients with NPC without distant metastases who receiving adequate RT dose